Cadrenal Therapeutics Inc (CVKD) Stock Price, Quote & News

Company Profile

Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions. The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-...

Industry: Biotechnology

Sector: Healthcare

Phone: 904 300 0701

Website: www.cadrenal.com

Address:

822 A1A North, Suite 306, Ponte Vedra, United States

StayPresent Aug. 26 at 2:49 PM

$CVKD half way there you pos, half way there.

0 · Reply

DominionSecurities Aug. 23 at 10:37 AM

$CVKD Cadrenal Therapeutics Inc is a clinical stage biotech with early development programs

0 · Reply

BHWinehouse Aug. 21 at 1:00 PM

$TNFA This isn't everyones cup of tea. I'm in and will gladly go through an r/s if and when that happens. Good promising pipeline is what I'm looking at. If it tanks it tanks. But, if it makes it to the finish line....$$$. As i have said before, $CVKD went through an r/s, and they have weathered it just fine because they too have a great product.. The real money takes time. Glta

2 · Reply

StayPresent Aug. 20 at 11:39 PM

$CVKD still a pos

0 · Reply

AIAgent Aug. 20 at 11:09 PM

$CVKD going to loose big

0 · Reply

BHWinehouse Aug. 19 at 5:00 PM

$TNFA For everyone bashing an r/s, check out $CVKD. Similar circumstances. Split went from .38 to $5.00, kept on going and I sold at $21 then repurchased at half that. It's about the pipeline....

3 · Reply

BioTechHealthX Aug. 14 at 4:09 PM

$CVKD Tecarfarin’s unique design and regulatory fast-track status could make Cadrenal the most exciting growth story in biopharma right now. https://biotechhealthx.com/biotech-news/cadrenal-therapeutics-inc-nasdaqcvkd/

0 · Reply

Johnveramont Aug. 14 at 2:10 PM

$CVKD loving the recent action very bullish

1 · Reply

Johnveramont Aug. 14 at 2:10 PM

$CVKD

0 · Reply

Channelchek Aug. 12 at 1:59 PM

Noble Capital Markets Research Report: Cadrenal Therapeutics ($CVKD) – 2Q25 Included Clinical Strategy Change and Manufacturing Progress Cadrenal Reports 2Q With Product News. Cadrenal reported a 2Q25 loss of $3.7 million or $(1.87) per share. During the quarter, the company announced a design modification for the upcoming tecarfarin clinical trial. The company also transferred its manufacturing technology to a CDMO and completed production scale-up in preparation for clinical trials. Cash on June 30, 2025 was $5.6 million. Read more: https://www.channelchek.com/news-channel/cadrenal-therapeutics-cvkd-2q25-included-clinical-strategy-change-and-manufacturing-progress

0 · Reply

Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 5, 2025, 6:00 AM EDT - 26 days ago

Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis

Jun 12, 2025, 8:00 AM EDT - 2 months ago

Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients

Jun 4, 2025, 8:00 AM EDT - 3 months ago

Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025

May 15, 2025, 7:30 AM EDT - 3 months ago

Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness

May 8, 2025, 8:00 AM EDT - 4 months ago

Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update

Apr 17, 2025, 9:40 AM EDT - 4 months ago

Cadrenal Therapeutics to Present at Inaugural Centri Capital Conference at Nasdaq

Apr 3, 2025, 8:00 AM EDT - 5 months ago

Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences

Mar 13, 2025, 4:05 PM EDT - 6 months ago

Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

Mar 4, 2025, 8:00 AM EST - 6 months ago

Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD

ABT

Feb 6, 2025, 9:00 AM EST - 7 months ago

Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin

Feb 5, 2025, 9:00 AM EST - 7 months ago

Cadrenal Therapeutics to Present at BIO CEO & Investor Conference

Jan 9, 2025, 8:44 AM EST - 8 months ago

Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Dec 31, 2024, 8:00 AM EST - 8 months ago

Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications

Dec 18, 2024, 9:00 AM EST - 9 months ago

Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings

Nov 19, 2024, 9:00 AM EST - 10 months ago

Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook

Nov 12, 2024, 9:00 AM EST - 10 months ago

CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS

Nov 7, 2024, 9:00 AM EST - 10 months ago

CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE

Nov 1, 2024, 8:00 PM EDT - 10 months ago

Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds

Oct 24, 2024, 9:00 AM EDT - 11 months ago

Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility

Oct 23, 2024, 9:00 AM EDT - 11 months ago

CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM

Sep 23, 2024, 4:15 PM EDT - 1 year ago

Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference

Aug 22, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients

Aug 20, 2024, 9:00 AM EDT - 1 year ago

Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients

Aug 20, 2024, 7:00 AM EDT - 1 year ago

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

CIA ELUT EUDA GDTC GOSS GOVX IMRN

Aug 14, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics to Present at Upcoming Investor Conferences

Aug 7, 2024, 4:05 PM EDT - 1 year ago

Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update

Aug 6, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs

ABT

Jul 17, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024

Jun 11, 2024, 4:15 PM EDT - 1 year ago

Cadrenal Therapeutics to Present at the Emerging Growth Conference on June 12, 2024

Jun 3, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients

ABT

May 23, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

May 9, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update

Apr 11, 2024, 4:30 PM EDT - 1 year ago

Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024

Apr 9, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts

Mar 11, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update

Feb 26, 2024, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference

Feb 8, 2024, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial

Jan 31, 2024, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical Conditions

Jan 24, 2024, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

Jan 4, 2024, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference

Dec 19, 2023, 9:00 AM EST - 1 year ago

Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price Target

Dec 12, 2023, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and Commercialization

Nov 30, 2023, 4:15 PM EST - 1 year ago

Cadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023

Nov 9, 2023, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics Provides Third Quarter 2023 Corporate Update

Oct 9, 2023, 4:15 PM EDT - 2 years ago

Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2023 Investor Conference

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Cadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist (Tecarfarin) Following Updates from the Recent European Society of Cardiology Congress

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Cadrenal Therapeutics Expands Evaluation of Tecarfarin for Patients with Antiphospholipid Syndrome (APS)

Aug 28, 2023, 4:15 PM EDT - 2 years ago

Cadrenal Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Aug 10, 2023, 9:00 AM EDT - 2 years ago

Cadrenal Therapeutics Provides Second Quarter 2023 Corporate Update

StayPresent Aug. 26 at 2:49 PM

$CVKD half way there you pos, half way there.

0 · Reply

DominionSecurities Aug. 23 at 10:37 AM

$CVKD Cadrenal Therapeutics Inc is a clinical stage biotech with early development programs

0 · Reply

BHWinehouse Aug. 21 at 1:00 PM

2 · Reply

StayPresent Aug. 20 at 11:39 PM

$CVKD still a pos

0 · Reply

AIAgent Aug. 20 at 11:09 PM

$CVKD going to loose big

0 · Reply

BHWinehouse Aug. 19 at 5:00 PM

$TNFA For everyone bashing an r/s, check out $CVKD. Similar circumstances. Split went from .38 to $5.00, kept on going and I sold at $21 then repurchased at half that. It's about the pipeline....

3 · Reply

BioTechHealthX Aug. 14 at 4:09 PM

0 · Reply

Johnveramont Aug. 14 at 2:10 PM

$CVKD loving the recent action very bullish

1 · Reply

Johnveramont Aug. 14 at 2:10 PM

$CVKD

0 · Reply

Channelchek Aug. 12 at 1:59 PM

0 · Reply

EfamhS Aug. 11 at 1:58 PM

$CVKD https://finance.yahoo.com/news/cadrenal-therapeutics-reports-second-quarter-120000504.html

0 · Reply

TheGreenery Aug. 9 at 11:35 PM

$CVKD @FeliciaVela pretty funny most of these account followed 3 stocks and all spread bullish sentiment yet they are all down so bad. You an absolute loser who's spreading lies stfu with all your accounts there's like 10 of them on here. .

0 · Reply

The_Claw Aug. 9 at 11:07 PM

$CVKD Bot bot, McBot.

0 · Reply

topstockalerts Aug. 7 at 5:09 PM

$CVKD where’s the floor now??

0 · Reply

Channelchek Aug. 7 at 1:45 PM

Noble Capital Markets Research Report: Cadrenal Therapeutics ($CVKD) – Tecarfarin Clinical Trial To Begin With Modified Design Cadrenal Announces New Trial Design. Cadrenal announced that it plans to begin a trial testing tecarfarin in patients who are starting renal dialysis, both with and without atrial fibrillation (ESKD-Afib). This design reflects recent studies showing that the first several months after starting dialysis are an ultra-high risk period for mortality and cardiac events. The trial will test tecarfarin efficacy in reducing these events and could begin in late 2025 to early 2026. Read more: https://www.channelchek.com/news-channel/cadrenal-therapeutics-cvkd-tecarfarin-clinical-trial-to-begin-with-modified-design

0 · Reply

Jhon05 Aug. 7 at 1:07 PM

$CVKD Even cows provide monthly income.

0 · Reply

Jhon05 Aug. 7 at 12:54 PM

$CVKD No news, no income, no hope, no stability, no honesty, you can't find investors that way.

1 · Reply

Jhon05 Aug. 7 at 12:50 PM

$CVKD Who buys into a stock that is constantly falling?

2 · Reply

Jhon05 Aug. 7 at 12:49 PM

$CVKD you can't find investors

0 · Reply

StayPresent Aug. 7 at 11:39 AM

$CVKD Trash

0 · Reply

BroadStocks Aug. 7 at 6:06 AM

$CVKD A bunch of bots making this thing trend..

0 · Reply

Joby099 Aug. 6 at 11:04 AM

$QBTS $CVKD $EQ $NVA $KULR

0 · Reply

Market Cap	26.53M
Revenue (ttm)	0.00
Net Income (ttm)	-10.65M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	15,100
Avg Vol	33,246
Day's Range	N/A - N/A
Shares Out	2.05M
Stochastic %K	45%
Beta	0.93
Analysts	Strong Sell
Price Target	$35.67